Top Qs
Timeline
Chat
Perspective
Amyris, Inc.
American biotechnology company From Wikipedia, the free encyclopedia
Remove ads
Amyris, Inc., founded in 2003, is a synthetic biotechnology company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.[1]
In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin.[2] In April 2019, the company raised $34-million in private placement of its common stock and warrants.
In 2020, Amyris received Bonsucro's Chain of Custody Certification, ensuring that the sustainability claims along the sugarcane supply chain are traceable from farmer to end user.[3] During the COVID-19 pandemic, the company collaborated with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.[4]
On August 9, 2023, Amyris filed for Chapter 11 bankruptcy protection and announced it will shut down its consumer brands amongst selling itself.[5] The company was delisted from Nasdaq and added to the OTC Markets. On May 7, 2024, the company emerged from bankruptcy. A new CEO, Kathy Fortmann, was installed and is today at the helm of the company where she is leading the 2030 strategy, which is focused on B2B customers.
Remove ads
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads